CG Oncology Inc. (CGON)
CGON Stock Price Chart
Explore CG Oncology Inc. interactive price chart. Choose custom timeframes to analyze CGON price movements and trends.
CGON Company Profile
Discover essential business fundamentals and corporate details for CG Oncology Inc. (CGON) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
25 Jan 2024
Employees
142.00
Website
https://cgoncology.comCEO
Arthur Kuan
Description
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
CGON Financial Timeline
Browse a chronological timeline of CG Oncology Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 7 Aug 2026
EPS estimate is -$0.70, while revenue estimate is $333.05k.
Earnings released on 8 May 2026
EPS came in at -$0.71 falling short of the estimated -$0.58 by -22.41%, while revenue for the quarter reached $1.08m , beating expectations by +139.05%.
Earnings released on 27 Feb 2026
EPS came in at -$0.51 surpassing the estimated -$0.61 by +16.39%, while revenue for the quarter reached $2.31m , beating expectations by +412.94%.
Earnings released on 14 Nov 2025
EPS came in at -$0.57 falling short of the estimated -$0.56 by -1.96%, while revenue for the quarter reached $1.67m , beating expectations by +2.71k%.
Earnings released on 8 Aug 2025
EPS came in at -$0.54 falling short of the estimated -$0.49 by -10.20%.
Earnings released on 13 May 2025
EPS came in at -$0.45 falling short of the estimated -$0.39 by -15.38%, while revenue for the quarter reached $52.00k , missing expectations by -56.00%.
Earnings released on 28 Mar 2025
EPS came in at -$0.48 falling short of the estimated -$0.41 by -17.07%, while revenue for the quarter reached $456.00k , beating expectations by +267.89%.
Earnings released on 14 Nov 2024
Earnings released on 8 Aug 2024
EPS came in at -$0.28 surpassing the estimated -$0.42 by +33.33%, while revenue for the quarter reached $111.00k .
Earnings released on 9 May 2024
EPS came in at -$0.36 falling short of the estimated -$0.35 by -2.86%, while revenue for the quarter reached $529.00k .
Earnings released on 26 Mar 2024
CGON Stock Performance
Access detailed CGON performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
